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Background: DNMT3A mutations represent one of the most frequent gene alterations detectable in acute myeloid
leukemia (AML) with normal karyotype. Although various recurrent somatic mutations of DNMT3A have been
described, the most common mutation is located at R882 in the methyltransferase domain of the gene. Because of
their prognostic significance and high stability during disease evolution, DNMT3A mutations might represent highly
informative biomarkers for prognosis and outcome of disease.
Methods: We describe an allele-specific PCR with a Blocking reagent for the quantitative detection of DNMT3A R882H
mutation providing the possibility to analyze the quantitative amount of mutation during the course of disease. Next,
we analyzed 62 follow-up samples from 6 AML patients after therapy and allogeneic stem cell transplantation (alloSCT).
Results: We developed an ASB-PCR assay for quantitative analysis of R882H DNMT3A mutation. After optimization of
blocker concentration, a R882H-positive plasmid was constructed to enhance the accuracy of the sensitivity of
quantitative detection. The assay displayed a high efficiency and sensitivity up to 10−3. The reproducibility of assay
analyzed using follow-up samples showed the standard deviation less than 3.1 %. This assay displayed a complete
concordance with sequencing and endonuclease restriction analysis. We have found persistence of DNMT3A
R882H mutations in complete remission (CR) after standard cytoreduction therapy that could be indicating presence of
DNMT3A mutation in early pre-leukemic stem cells that resist chemotherapy. The loss of correlation between NPM1 and
DNMT3A in CR could be associated with evolution of pre-leukemic and leukemic clones. In patients with CR with
complete donor chimerism after alloSCT, we have found no DNMT3A R882H. In relapsed patients, all samples showed
an increasing of both NPM1 and DNMT3A mutated alleles. This suggests at least in part the presence of NPM1 and
DNMT3A mutations in the same cell clone.
Conclusion: We developed a rapid and reliable method for quantitative detection of DNMT3A R882H mutations in
AML patients. Quantitative detection of DNMT3A R882H mutations at different time points of AML disease enables
screening of follow-up samples. This could provide additional information about the role of DNMT3A mutations in
development and progression of AML.
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Somatic mutations in the DNA nucleotide methyltrans-
ferase 3A gene (DNMT3A) have been reported approxi-
mately in 22 % of de novo acute myeloid leukemia
(AML) and 36 % of cytogenetically normal AML [1].
Mutations in DNMT3A were first described by Ley et al.
using whole genome sequencing [2]. DNMT3A belongs
to the mammalian methyltransferase gene family which
is responsible for tissue-specific gene expression [3].
DNA methyltransferases are the key enzymes for gen-
ome methylation, which plays an important role in epi-
genetically regulated gene expression and repression.
DNMT3A together with other methyltransferases con-
ducts de novo methylation of cytosine residues in CpG
islands by the enzymatic addition of methyl residues
from S-adenosyl-L-methionine to the 5-carbon atom of
the cytosine ring. CpG islands are often located proximate
to gene promoters thereby regulating their activation.
Actively transcribed genes display unmethylated CpG
islands which supports the euchromatin structure whereas
methylated CpG islands are associated with untranscribed
genes stabilizing the heterochromatin structure [4, 5].
Cancer genomes are most commonly characterized by
global DNA hypomethylation. However, cancer cells also
typically exhibit distinct regions of DNA hypermethyla-
tion, which are particularly well characterized in the CpG
islands of promoter regions of tumor-suppressor genes.
Although various recurrent DNMT3A mutations have
been described, the most common mutation affects resi-
due R882 within the methyltransferase domain. DNMT3A
mutations are typically heterozygous [2, 6].
The biology of DNMT3A is not fully understood. Holz-
Schietinger et al. reported that mutations in DNMT3A
could retard its function by multiple mechanisms as
changes in the catalytic properties, its processivity and the
disruption of interaction with binding partners [7]. Fur-
thermore, Russler-Germain et al. found that mutations in
the position R882 inhibit the formation of active tetramers
of DNMT3A [8]. The impaired function of mutated
DNMT3A leads to a hypomethylated genome of myeloid
cells possibly promoting leukemogenesis and influencing
disease outcome [9].
Since the DNMT3A mutations are present in the early
pre-leukemic cells, this alteration seems to be a “founder”
mutation, which can be implicated as functional compo-
nents of AML evolution [10, 11]. DNMT3A mutations are
highly associated with mutations in the nucleophosmin 1
gene (NPM1), fms-related tyrosine kinase 3 gene (FLT3),
and isocitrate dehydrogenase 1 gene (IDH1) [12, 13].
Several studies reported a negative prognostic impact
of DNMT3A mutations [12–16]. Prognostic effect is
known to depend on certain biological factors as well as
a combination of cytogenetics and other mutations such
as those in FLT3 and NPM1.Some authors have found stability of DNMT3A muta-
tions during the course of disease; therefore those aber-
rations could be potential marker for minimal residual
disease (MRD). Furthermore, the presence of DNMT3A
mutations seems to be associated with the incidence of
FLT3-ITD-positive clones at relapse possibly influencing
the responsiveness of FLT3-positive cases to chemother-
apy [17, 18]. Last published data have demonstrated that
DNMT3A mutations are also detectable in AML patients
in long-term complete remission (CR) and can occur in
pre-leukemic stem cells [10, 11, 19]. The identification of
pre-leukemic cells with genetic mutations in CR has im-
portant implications for the MRD monitoring. Moreover,
the persistence of DNMT3A mutations in CR may have
important implications for the management of AML.
Recent discoveries utilizing whole-exome sequencing
in a large cohort of persons, unselected for cancer or
hematologic phenotypes have demonstrated somatic
mutations in significant proportion of persons particu-
larly which older than 65 years. Moreover, DNMT3A
gene together with TET2, ASXL1, and PPM1D had dis-
proportionately high numbers of somatic mutations [20,
21]. The data suggest that mutations in pre-leukemic
cells could precede leukemia. Furthermore, DNMT3A
mutations could drive clonal expansions. Based on these
data, DNMT3A mutation might represent highly inform-
ative biomarkers for AML. Thus, a negative prognostic
impact and, in addition, conflicting reports on the po-
tential role of DNMT3A mutations for the evolution of
leukemic stem cell, require fast, reliable, quantitative and
available methods for detection of mutation.
Sanger sequencing is well-established but not very sensi-
tive as well as time-consuming and cost-intensive method.
HRM analysis provides the possibility of high throughput
screening of mutations, but data interpretation occasion-
ally can be difficult. Therefore, good validated controls
and standards are needed. Previously we reported a rapid
and reliable restriction fragment length polymorphism
based method for the qualitative detection of DNMT3A
R882H mutation [22]. Current quantitative established
assays have low sensitivity and therefore cannot be used as
reliable methods for MRD diagnostic. Here, we describe
an Allele-Specific PCR with a Blocking reagent (ASB-
PCR) for the quantitative detection of DNMT3A R882H
mutation with sensitivity up to 10−3 providing the possibil-
ity to analyze the quantitative amount of this mutation for
routine diagnostic during the course of disease.
Methods
Patient and control materials
Bone marrow (BM) samples from 16 newly diagnosed
AML patients, 8 DNMT3A positive and 8 DNMT3A wild
type (wt), were included in the study. In addition, we an-
alyzed 62 follow-up samples from 6 DNMT3A positive
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transplantation (alloSCT). All patients were treated at
the University Clinic Charité from September 2009 to
May 2013. Diagnoses were established according to the
WHO criteria [23]. Written informed consent was ob-
tained from all patients in accordance with the Declar-
ation of Helsinki and the ethical guidelines of the Charite
University School of Medicine, which approved this study.
In 6 AML patients included in the follow up study, induc-
tion therapy consisted of “7 + 3” therapy with Cytosine
Arabinoside and Daunorubicine. Second part of induction
with “7 + 3” started at day 22, if at day 15 count of BM
blasts were reduced. Once complete remission (CR) was
achieved, 2–4 courses of consolidation chemotherapy with
high-dose Cytosine Arabinoside were administered. At
1-st CR or at 2-nd CR patients were allocated to alloSCT.
Control material for DNMT3A mutation included
DNA from K562 cell line (wt) and constructed plasmid
which contains the R882H mutation.
DNA extraction
Mononuclear cells (MNCs) from BM aspirates were iso-
lated using Ficoll density centrifugation as described
[24]. DNA was extracted using Allprep DNA/RNA mini
kit (Qiagen) from 1*107 MNCs as recommended by the
manufacturer. DNA yields ranged from 50 to 300 ng/μl.
Allele-Specific PCR with a Blocking reagent (ASB-PCR)
The ASB-PCR assay was designed using Primer3, Oligocalc
and UCSC software. We used an allele-specific reverse
primer containing the mutational spot (R882H G >A) at
its 3′-end. The blocking sequence was developed comple-
mentary to the wt allele. The discriminating base was
located in the middle of the blocker. To prevent elongation
by Taq polymerase, a phosphate group was added to the
3′-end of the blocker. For fluorescence detection, a Taq-
Man probe was used (Fig. 1). All primer sequences are
listed in Table 1. Further properties, such as melting
temperature were developed in accordance with Morlan
et al. [25]. The reaction mixture contained 12.5 μl 2 × Ab-
solute qPCR Mix (Applied Biosystems), 10 pmol of each
forward and reverse allele-specific primer, 40 pmol of ASB-
Blocker, 5 pmol of probe, and 30 ng of DNA in a finalFig. 1 Assay design of ASB-PCR. Primers and probe are located in exon 23
its 3′-end whereas the wt spot is incorporated in the middle of the blocker
probe which was designed near to the forward primer (13 bp distance)reaction volume of 25 μl. Reaction was run at 95 °C for
10 min followed by 40 cycles of denaturation at 95 °C for
20 s and annealing/elongation at 67 °C for 45 s on a Rotor
Gene 6000 Real-Time PCR Cycler (Qiagen).
Plasmid preparation
For absolute quantification, a plasmid containing the
DNMT3A R882H G > A mutations was constructed. The
template was amplified using ASB-PCR primers, and the
fragment size (94 bp) was analyzed on a 1.5 % agarose
gel. The plasmid was prepared using the TOPO TA
cloning Kit (Invitrogen) and chemically competent E.coli
as per the manufacturer’s instructions. Fragment inser-
tion was checked using DNA sequencing with provided
M13 forward and reverse primers.
DNA sequencing and endonuclease restriction analysis of
DNMT3A mutations
PCR sequencing reaction was performed as previously
described [22]. Amplified products were purified using
the PCR Purification Kit (Qiagen) according to the man-
ufactures instruction. Sequencing was performed using
ABI310 Genetic Analyzer (Applied Biosystems), and data
were analyzed using DNA Sequencing Analysis Software
v.5.2.0. Endonuclease restriction analysis of DNMT3A
R882H mutation was performed using Fnu4HI (New
England Biolabs) as previously reported [22].
Qualitative and quantitative evaluation of mutations
Qualitative evaluation for presence of NPM1, DNMT3A,
IDH1 and IDH2 mutations were performed by Sanger
sequencing using ABI310 Genetic Analyzer (Applied
Biosystems) as previously described [22]. FLT3-ITD and
FLT3 D835Y were quantified by fluorescence fragment
analysis on a 310 Genetic Analyzer (Applied Biosystems)
as previously described [26]. Quantitative analysis of pres-
ence NPM1 mutations was performed by real-time PCR
using Rotor Gene 6000 Real-Time PCR Cycler (Qiagen).
The reaction mixture contained 12.5 μl 2 × Absolute
qPCR Mix (Applied Biosystems), 30 pmol of each forward
and reverse allele-specific primer, 10 pmol of forward and
6 pmol of reverse HCK probes, 25 pmol of each FAM-
MGB and HEX probes, and 50 ng of DNA in a reactionof DNMT3A. The allele-specific primer contains the mutational spot at
(red box). Fluorescence detection was performed with a TaqMan
Table 1 Oligonucleotides used in this study
Name Sequence Application Tm [°C]
DNTM3A-Ex23F 5′-GTGTGGTTAGACGGCTTCC Sequencing 59.5
DNMT3A-Ex23R 5′-CTCTCCCACCTTTCCTCTG Sequencing 59.5
ASB-F 5′- CAGCGGAGCGAAGAGGTG ASB-PCR 60.8
Allele-specific 5′- CGTCTCCAACATGAGCCA ASB-PCR 56.3
ASB-Blocker 5′- CATGAGCCGCTTGGCGAG-PH ASB-PCR 60.8
ASB-Probe 5′- FAM-CTCCATGACCGGCCCAGCAGTC-BBQ ASB-PCR 69.5
The mutational spot in the allele-specific primer and blocker sequence is bold and punctuated. ASB, indicates Allele-Specific PCR with a Blocking reagent; DNMT3A,
indicates DNA methyltransferase 3 gene
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15 min followed by 45 cycles of denaturation at 95 °C for
15 s and annealing/elongation at 60 °C for 1 min.
Results
ASB-PCR assay performance
At first, we have tested the performance of ASB-PCR by
standard PCR amplification and agarose gel electrophoresis.Fig. 2 Performance of ASB-PCR. ai Qualitative analysis of the specificity of A
significant change in the amplification properties. aii Quantitative analysis o
analysis displayed a Ct difference of 11–14 cycles between R882H mutatedSpecificity of ASB-PCR was verified using Sanger
sequencing. To determine the optimal blocker concen-
tration, PCR was performed with 40 μM and 80 μM of
blocker, successively. A specific amplification of mu-
tated DNA was determined producing a PCR fragment
of approximately 94 bp. DNA of the wt sample was also
amplified, but with a considerably lower efficiency com-
pared to R882H-positive DNA (Fig. 2.ai). No significantSB-PCR. Enhancement of blocker concentration to 80 μM showed no
f Ct-changes induced by addition of 40 μM blocker. b Quantitative
DNA and wt DNA. NTC, non-template control; wt, wild type
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and 80 μM of blocker. However, the presence of 40 μM
blocker in the reaction led to detection of R882H
around 2 Ct’s earlier compared to the assay without
blocker (22.64 vs. 24.38; Fig. 2.aii). Therefore, 40 μM of
blocker were used for further applications. Next, we de-
termined the quantitative performance of the assay
(Fig. 2.b). The fluorescence signal of mutated samples
exceeded the threshold 11–14 cycles earlier as com-
pared with wt samples (27.64/27.83 vs. 38.28/41.41).
Based on this analysis, we chose a Ct-value of 35 as the
cut-off limit.
Subsequently, the sensitivity of ASB-PCR was studied.
First, a dilution series of genomic DNA was prepared
ranging from 50 ng to 1 ng (Fig. 3.a). Differentiation be-
tween wt and R882H samples was possible for all dilu-
tion steps. One ng of R882H DNA was detected 4 cycles
earlier compared with 30 ng of wt DNA (32.09 vs.
36.31). In addition, a dilution series of R882H-positive
DNA with wt DNA was analyzed (Fig. 3.b). Discri-
mination of 1 % of R882H-positive DNA was possibleFig. 3 Analysis of PCR sensitivity using serial dilutions of DNA (a) and (b) dexceeding the threshold approximately 3 cycles earlier as
the wt DNA (33.60 vs. 36.31). The cut-off limit of Ct =
35 was constant for these analyses. To enhance the ac-
curacy of the sensitivity determination of quantitative
detection of the mutation, a R882H-positive plasmid was
constructed.
Plasmid performance and absolute quantification
We have generated a plasmid which contains a homozy-
gous R882H mutation (Fig. 4). Significant differentiation to
the wt DNA was possible up to a dilution of 10−1 copies. A
copy number of 10−2 exceeded the threshold approxi-
mately at the cut-off value of 35 cycles (Fig. 5.a). However,
the assay effectiveness was distinct when the plasmid con-
taining a homozygous R882H mutation was compared
with heterozygous patient samples. Two samples obtained
from AML patients at diagnosis containing approximately
50 % of DNMT3A R882H mutations exceeded the thresh-
old at a similar cycle as the 10° dilution of the plasmid
(29.14/29.11 vs. 28.65; Fig. 5.b). The initial mutation
portion was determined by Sanger sequencing. Sinceilution of mutated DNA with wt DNA
Fig. 4 Sequence of R882H plasmid. a Heterozygote R882H mutation in a patient sample. The mutational spot is indicated by the red box. Both,
guanine (wt) and adenine (mutation) were detected. b Homozygote R882H mutation in the generated plasmid. The mutational spot is indicated
by the red box. The sequence displays only the mutated adenine base and no wt guanine base
Berenstein et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:55 Page 6 of 11the absolute quantification was not possible in this set-
ting, we performed an absolute quantification by the
percentage of mutated allele. Based on the previous
measurement, the 10° plasmid dilution was defined to
contain 50 % of DNMT3A R882H mutation. Fig. 5.c
demonstrates a possibility of reliable quantification of
patient samples using this setting. The sample containing
50 % of DNMT3A R882H was detected at the same cycle
as the 100 plasmid dilution (25.15 vs. 25.07). In addition,
the sample with 25 % R882H mutation exceeded the
threshold at a similar cycle compared to the 5*10−1 plas-
mid controls (26.33 vs. 26.1). The assay displayed a high
efficiency between 0.98 and 1.03 (Fig. 5.b and d). The sen-
sitivity of assay ranged up to 10−3.
In addition, follow-up samples of one patient were an-
alyzed three times to examine the reproducibility of
assay results. As shown in Table 2 the standard deviation
was ≤ 3.1 %.
Assays concordance
Next, the concordance of different methods for detec-
tion of DNMT3A mutation was examined.
Initially, 25 samples from AML patients were analyzed
using DNA sequencing. Next, endonuclease restriction
analysis and ASB-PCR were used (Fig. 6). We have pre-
viously described that endonuclease restriction analysis
has a perfect concordance with Sanger sequencing and
is characterized by high sensitivity [22]. Qualitative
assessment of band sizes (Fig. 6.a) corresponded to
quantitative detection of R882H mutation using ASB-PCR (Fig. 6.b) in follow up samples from patient A, B,
C, und E. Patient D showed no DNMT3A R882H muta-
tion using both methods. For example, increasing of
DNMT3A R882H mutation in samples from patient C
from 0.55 % to 13.4 % by ASB-PCR assay (Fig. 6.b)
matched with a gain of band by endonuclease restriction
analysis (Fig. 6.a). A cut-off of Ct = 35 was also applic-
able for analysis of follow-up samples. No false negative
or positive signals were detected using the endonuclease
restriction and ASB-PCR.
Analysis of follow-up samples from AML patients
We analyzed 62 follow up constitutive samples obtained
from 6 AML patients at diagnosis, after induction, consoli-
dation therapy, and after alloSCT. All patients included in
the follow-up analysis harbored a NPM1 mutation at diag-
nosis. This enabled comparison of DNMT3A stability dur-
ing both CR and complete molecular remission (molCR)
using the well-established marker for detection of MRD.
The main characteristics, karyotype, concurrent muta-
tions, percent of DNMT3A mutation, and MRD data of
these patients are shown in Table 3. Median age was
55 years (range 43–60 years), and the median survival time
by the end of this study was 30 months (range 9–52
months).
For most analyzed patient, a DNMT3A R882H mutation
was detectable after induction and consolidation therapy.
The percentage of mutated allele was not constant and
fluctuated in the course of disease. For example percent-
age of R882H in follow-up samples of patient 6 ranged
Fig. 5 Absolute quantification of DNMT3A R882H mutations. Values of ASB-PCR are listed in the corresponding table. a Analysis of copy number
dilutions of the R882H homozygote plasmid. Patient samples with approximately 50 % of R882H mutated allele are indicated by dotted lines; the
10° plasmid dilutions are pink line. b The standard curve (copy numbers over cycle). Patient samples with 50 % R882H are shown as a blue diamond
and a green triangle. Wt samples are shown as red quadrats. R2 = correlation coefficient. B = Intercept with the ordinate. M = Slope of the standard
curve. c Absolute quantification was performed by percentage of mutated allele in a sample. Plasmid concentrations were adjusted to 50 % and 25 %
of mutated R882H allele according to the measurement of heterozygote patient samples (dotted lines). d Standard curve (%R882H over cycle). The
dotted red line shows the limit of 100 % R882H mutated allele in a sample. Patient samples are shown as a blue diamond and a green triangle.
wt samples are shown as red quadrats. R2 = correlation coefficienct. B = Intercept with the ordinate. M = Slope of the standard curve
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in CR and molCR according to analysis of NPM1, a signifi-
cant proportion of DNMT3A R882H mutation could be
detected. In patients 1, 2, 3, 4, and 5 (Table 3), DNMT3A
mutation was present at diagnosis and in CR after stand-
ard therapy. The amounts of mutation were decreased, for
example, from 21.45 % to 16.5 % in patient 1 and from
14.95 % to 1.2 % in patient 4. In patient 2 (Table 3),
amount of mutated allele was later increased despite theTable 2 Reproducibility of ASB-PCR






187-5 31.35 33.05patients was in CR with slight positive or negative MRD.
The percentage of mutated allele was higher (30.8 %) as
compared to diagnostic sample (11.95 %). At this time
point, the patient exhibited thrombocytopenia in periph-
eral blood with normal blasts count in BM. In samples
obtained in CR after alloSCT (Patients 1, 2, and 3, Table 3)
with complete donor chimerism (CDC), DNMT3A muta-
tion was not found. Interestingly, NPM1 mutation was







Fig. 6 Concordance of ASB-PCR. a Representative endonuclease restriction analysis of follow-up samples of five patients (A-E). Wild type samples
show two bands at 190 bp and 114 bp. Positive samples display three bands at 289 bp, 190 bp, 114 bp due to the loss of a restriction site of
Fnu4HI caused by the mutation. Hyperladder II (Bioline) was used as marker. b Results of ASB-PCR analysis
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DNMT3A mutation was not detectable in patients 1, 2, and
3 after alloSCT, in CR with CDC. After alloSCT no
DNMT3A R882H mutation was detected in cases when the
patient displayed a complete or high percent of donor cells.
In relapse of AML, significant proportion of DNMT3A
R882H mutation was detected in all relapsed patients
(Table 3). For instance, percentage of R882-positive allele
increased significantly in patient 4 at relapse from 0 % to
9.25 % correlating with the molecular relapse detected
by the percentage of NPM1 and reduced amount of
donor cells (10 %). In patient 6 the decreasing of donor
cells from 92 % to 60 % associated with a growing of
R882-positive allele from 0 % to 0.45 %. However, per-
centage of NPM1 did not increase and a relapse was not
diagnosed. This patient underwent match related alloSCT
after reduced intensity conditioning, and demonstrated
delayed engraftment with slowly growing of donor cells.
Notably, in the CR, the majority of patients showed a high
level of DNMT3A mutations despite the low or negative
rates of NPM1 mutation. In relapse, levels of both muta-
tions have been increased.
Discussion
Last years, potential role of DNMT3A mutation for
prognosis and outcome of AML has been extensively
studied. Several authors have shown a negative impact
of DNMT3A mutations on outcomes of AML patient
[12, 13, 15, 18, 27–29]. DNMT3A mutation has been
shown an independent poor prognostic factor for overall
survival and relapse-free survival [15]. Currently, only
few methods for the quantitative detection of DNMT3A
R882H mutations are available [19, 30]. Here, we devel-
oped an ASB-PCR assay that allows discrimination be-
tween wt and mutated DNMT3A and quantification of
R882H allele in one reaction. The main feature of this
assay is the combination of an allele-specific primer witha competitive blocker as described by Morlan et al. [25].
Features of DNMT3A R882H sequence allowed introduc-
tion of a purin-purin-mismatch (G-A) to the allele-specific
primer leading to its high selectivity. Thus, a significant
amplification difference for the wt and mutant allele was
seen also without the use of the competitive blocker. Add-
ing blocker enhanced selective amplification of R882H-
mutated allele that lead to earlier detection of mutation.
Furthermore, the maximum Ct difference between wt and
mutated allele was 14 cycles. Thereby, effectiveness of the
blocker is caused by intersection with the allele-specific
primer and location of the discriminating base in the mid-
dle of the blocker sequence. In contrast, the allele-specific
primer includes the discriminating base at its 3′-end.
In addition to the enabling of discrimination between
wt and mutant allele, the assay had to facilitate analysis
of follow-up samples that contain a low percentage of
mutated allele. The high sensitivity of 10−3 and the pos-
sibility to use low DNA amounts, up to 1 ng, make this
approach feasible.
Here, absolute quantification was performed by the
percentage of mutated R882H allele in a sample. Since
the generated plasmid contained a homozygous R882H
mutation the amplification characteristics using ASB-
PCR were different as compared to patient samples
containing the heterozygous mutation. Possibly, the
missing competition between wt and mutant allele dur-
ing the amplification of plasmid DNA leads to a more
efficient enrichment of mutant R882H generating higher
Ct values. Modification of plasmid concentrations ac-
cording to the percentage of mutated allele in the patient
samples determined by sequencing enabled a reliable
absolute quantification. Alternatively, the generation of an
additional plasmid containing the wt allele is possible. Ab-
solute quantification can be performed by combining the
wt plasmid with different proportions of the plasmid con-
taining the mutated allele [31].
Table 3 Quantitative analysis of DNMT3A R882H in follow-up samples from 6 AML patients
Patient Age/Gender FAB Karyotype Mutations at
diagnosis
Disease status DNMT3A % NPM1 log FLT3 Ratio Outcome/OS
1 52/F M4 46,XX NPM1 DS 21,45 1^106 0,72 CR/9+
FLT3-ITD CR after CT 16,4 1^-5 0
FLT3-TKD2 CR, day+28 after alloSCT , CDC 0 0 0
DNMT3A CR, day+195 after alloSCT, CDC 0 0 0
2 60/M M2 46,XY, del(9q) NPM1 DS 11,95 1^105 CR/31+
DNMT3A CR after IT 5,8 1^10-2
CR after CT 0,05 1^10-4




CR, day+26 after alloSCT, 98 % DC 0 0
CR, day+73 after alloSCT (CDC) 0 0
3 43/F M4 46,XX NPM1 DS 17,9 1^105 0,78 CR/52+
FLT3-ITD CR, day+563 after alloSCT, CDC 0 1^10-5 0
DNMT3A CR, day+731 after alloSCT, CDC 0 1^10-4 0
CR, day+1082 after alloSCT, CDC 0 0 0
CR, day+1445 after alloSCT, CDC 0 0 0
4 50/M M4 46,XY NPM1 DS 14,95 1,0^105 0,41 R/17+
FLT3-ITD CR after IT 1,6 1^10-4 0
DNMT3A CR after CT 1,2 1^10-5 0
CR, day+40 after alloSCT, CDC) 0 1^10-4 0
CR, day+130 after alloSCT, CDC 0,1 0 0
CR, day+217 after alloSCT, CDC 0 0 0
R, day+306 after alloSCT,
10 % DC
9,25 1^105 0
R, day+373 after alloSCT, 15 % DC 11,7 1^104 0,25
5 50/F 5a 46,XX NPM1 DS 22,15 1^105 0,5 CR/26
FLT3-ITD CR after IT 0,35 1^10-4 0
DNMT3A CR after IT 0,2 1^10-4 0
IDH1 CR after CT 0,1 1^10-4 0
CR after CT 0,05 0 0
CR, day+29 after alloSCT, CDC 0,05 1^10-4 0
CR, day+71 after alloSCT, CDC 0 1^10-5 0
R, day+114 after alloSCT,
90 % DC
0,05 1^10-4 0
CR, day+174 after alloSCT, CDC 0 0 0
CR, day+215 after alloSCT, CDC 0 0 0
6 71/M 5a 46,XY NPM1 DS 12,75 1^104 CR/46+
DNMT3A CR after IT 0,1 1^10-2
IDH1 CR after CT 0,1 1^10-4
IDH2 CR after CT 1,65 1^10-4
CR 0,1 1^10-4
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CR, day+27 after alloSCT, 92 % DC 0 1^10-4
CR, day+80 after alloSCT, 60 % DC 0,45 0
CR, day+91 after alloSCT, 65 % DC 0,15 1^10-4
CR, day+208 after alloSCT 14 % DC 1,25 0
CR, day+279 after alloSCT, CDC 0 0
CR, day+570 after alloSCT, CDC 0 0
FAB French–American–British classification systems, DS primary diagnosis, IT induction therapy, CT consolidation therapy, CR complete remission, R Relapse,
alloSCT allogeneic stem cell transplantation, CDC complete donor chimerism, DC donor cells
+patient alive at the end of study. Samples after alloSCT are bold
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concordance with other analysis methods is important.
ASB-PCR displayed a perfect concordance with sequen-
cing and endonuclease restriction analysis [22]. This ac-
counts for a high specificity of the assay. However, because
low amplification of wt samples is present a wt control
should be run together with patient samples. Here, the
cut-off value of Ct = 35 was applicable in every run but this
could depend on the PCR reagents and machine used for
Real-Time quantification.
To demonstrate the need and effectiveness of new
established method, we analyzed 62 follow-up samples
from 6 AML patients after therapy and alloSCT. More-
over, data about the stability of DNMT3A mutation dur-
ing the course of disease are restricted and controversial.
Previously published studies have demonstrated that
DNMT3A mutations are stable at relapse [12, 15]. Thol
et al. found that the mutations disappeared at CR and
recurred at relapse in one patient [12]. Later, Hou et al.
reported persistence of DNMT3A mutations at CR in 5
patients, which later achieved relapse and died of disease
progression. These data could relate the persistence of
DNMT3A mutations and high risk of relapse [18]. Re-
cently, Pløen et al. have identified persistence of DNMT3A
mutations in long-term remission of patients with AML
that received cytoreduction or palliative therapy [19].
Using cell-sorting, the authors showed that DNMT3A mu-
tations were present in T-cells and B-cells at diagnosis in
some patients, and also in T-cells several years after
diagnosis. The presence of DNMT3A in both B-cells and
T-cells could lead to the assumption that mutation had
occurred in an early pre-leukemic stem cell prior to the
acquisition of other genetic events, and could be resistantto chemotherapy [19]. Therefore, further exploration of
the role of DNMT3A R882H mutations for the progres-
sion of AML disease is needed.
In accordance with previous studies, we found persist-
ence of DNMT3A R882H mutations after standard
cytoreduction therapy. In most cases the amount of mu-
tated allele was lower as compared with the diagnostic
sample. But in one case (Patient 2, Table 3) we have
found an increasing of DNMT3A R882H allele in CR
without relapse signs. Furthermore, NPM1 remained
negative indicating potential persistence of a different
clone. The permanent presence of DNMT3A R882H
after therapy in deep CR could be indicating presence of
DNMT3A mutation in early pre-leukemic stem cells that
resist chemotherapy. This could also explain the loss of
correlation between NPM1 and DNMT3A because the
clonal expansion of pre-leukemic stem cells could ori-
ginate independent of NPM1 positive clones [10, 11]. In
relapse, all samples showed an increasing of both NPM1
and DNMT3A mutated alleles. This suggests at least in
part the presence of NPM1 and DNMT3A mutations in
the same cell clone. After alloSCT in patients in CR with
complete donor chimerism we have no found DNMT3A
R882H. This data suggests the removal of leukemic stem
cells after alloSCT and indicates the importance of
alloSCT for high risk AML patients.
In summary, we developed a rapid, sensitive and specific
method for quantitative detection of DNMT3A R882H
mutations in AML patients. This assay could be easily ap-
plicable for routine screening of DNMT3A R882 mutation
not only at time of diagnosis but also after the treatment.
Quantitative detection of DNMT3A R882H mutations at
different time points of AML disease enables screening of
Berenstein et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:55 Page 11 of 11follow-up samples. This could assist to evaluate response
to therapy and provide additional information about the
role of DNMT3A mutations in development and progres-
sion of AML.
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